AbbVie Inc. $ABBV Shares Sold by Hilton Head Capital Partners LLC

Key Points

• Hilton Head Capital Partners cut its AbbVie stake by 63.4% in the third quarter, selling 4,594 shares and retaining 2,651 shares valued at approximately $694,000. Institutional investors and hedge funds still own 70.23% of AbbVie.
• AbbVie shares were trading near their 52-week high at $286.88, while the company reported quarterly earnings and revenue above analyst expectations. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $279.86.
• AbbVie declared a quarterly dividend of $1.73, equivalent to $6.92 annually and a 2.4% yield. The company also received positive product news after the FDA approved a subcutaneous induction regimen for SKYRIZI in Crohn’s disease.

Hilton Head Capital Partners LLC cut its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 63.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,651 shares of the company's stock after selling 4,594 shares during the quarter. Hilton Head Capital Partners LLC's holdings in AbbVie were worth $694,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Lifelong Wealth Advisors Inc. raised its stake in AbbVie by 2.1% in the 3rd quarter. Lifelong Wealth Advisors Inc. now owns 1,755 shares of the company's stock valued at $459,000 after purchasing an additional 36 shares during the last quarter. James T. Borello RIA lifted its stake in shares of AbbVie by 3.5% in the third quarter. James T. Borello RIA now owns 1,192 shares of the company's stock worth $312,000 after buying an additional 40 shares in the last quarter. ACT Advisors LLC. lifted its stake in shares of AbbVie by 2.5% in the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company's stock worth $425,000 after buying an additional 41 shares in the last quarter. Willner & Heller LLC lifted its stake in shares of AbbVie by 0.7% in the second quarter. Willner & Heller LLC now owns 5,852 shares of the company's stock worth $1,472,000 after buying an additional 43 shares in the last quarter. Finally, B.O.S.S. Retirement Advisors LLC boosted its position in AbbVie by 3.1% during the second quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company's stock worth $359,000 after acquiring an additional 43 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Trading Up 0.4%

NYSE ABBV opened at $286.88 on Tuesday. The stock has a fifty day simple moving average of $266.18 and a 200-day simple moving average of $235.62. The stock has a market cap of $506.85 billion, a PE ratio of 81.04, a P/E/G ratio of 1.30 and a beta of 0.24. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $291.40.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. AbbVie's revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the firm posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts predict that AbbVie Inc. will post 13.93 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a $1.73 dividend. The ex-dividend date is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.4%. AbbVie's payout ratio is 195.48%.

Analyst Upgrades and Downgrades

ABBV has been the subject of a number of recent research reports. Leerink Partners increased their price objective on shares of AbbVie from $245.00 to $279.00 and gave the company an "outperform" rating in a report on Wednesday, August 5th. UBS Group increased their price target on AbbVie from $260.00 to $275.00 and gave the company a "neutral" rating in a report on Tuesday, October 6th. The Goldman Sachs Group lifted their price objective on AbbVie from $258.00 to $294.00 and gave the stock a "neutral" rating in a research report on Friday. Erste Group Bank raised AbbVie from a "hold" rating to a "buy" rating in a research note on Wednesday, August 5th. Finally, Guggenheim restated a "buy" rating and issued a $288.00 target price on shares of AbbVie in a report on Friday, October 9th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, AbbVie presently has an average rating of "Moderate Buy" and a consensus price target of $279.86.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The U.S. Food and Drug Administration approved a subcutaneous induction regimen for AbbVie’s SKYRIZI in adults with moderately to severely active Crohn’s disease. The needle-based treatment option may improve convenience and support the drug’s continued growth across immunology indications. FDA approves subcutaneous SKYRIZI regimen
• Positive Sentiment: Goldman Sachs raised its price target for ABBV to $294, signaling continued confidence in the company’s outlook and providing a bullish valuation reference. Goldman Sachs raises AbbVie price target
• Positive Sentiment: Reports that Citadel has built an approximately $900 million position in AbbVie may boost sentiment by highlighting institutional interest in the company’s dividend and growth profile. Citadel AbbVie position
• Neutral Sentiment: Options markets imply roughly a 5% move around the October 30 earnings release, indicating that investors expect significant volatility as they assess results and forward guidance. AbbVie options and earnings volatility
• Neutral Sentiment: Coverage continues to describe AbbVie as an attractive, income-focused “Dividend King,” although its high earnings multiple makes future performance dependent on sustained earnings growth. AbbVie Dividend King coverage
• Negative Sentiment: Erste Group Bank reduced its EPS forecast and expressed a weak outlook for AbbVie’s fiscal 2026 earnings, creating a counterweight to the favorable product and institutional news. Erste Group lowers AbbVie EPS forecast

Insider Buying and Selling at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the business's stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 0.06% of the company's stock.

AbbVie Company Profile

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.